Melanoma landmark study to develop personalised cancer treatment
26 August 2015
A leading team of scientists and doctors, working on several different continents have joined forces to discover the most deadly form of skin cancer – cutaneous melanoma – has four distinct subtypes.
Researchers from Melanoma Institute Australia (MIA) played a major role in the global study, which it is hoped will lead to improved treatment known as ‘personalised medicine’ for advanced melanoma patients. Ninety-eight Australian patients contributed their DNA to the research.
MIA’s Research Director and Co-Director, Professors Graham Mann and Richard Scolyer, both played integral roles in the five year study, working on the analysis of samples from 331 patients from around the world. They also helped write and develop a paper which involved over 300 researchers from countries including the United States, Germany and Canada who contribute to ‘The Cancer Genome Atlas’ (TCGA) project.
Scientists are confident the discovery will lead them to being able to develop more precise and better targeted cancer treatment in the future.
Commenting on the results, MIA Research Director, Professor Graham Mann said: “This is a fantastic global effort and it’s wonderful to see that MIA patients here in Australia, have played such a significant role in helping us conduct this landmark study. We are very grateful to them.
“The results provide us with a framework so we can classify this disease in an extremely detailed way. We can then make more focused decisions on both targeted and immunotherapy treatments, ultimately giving our patients the best possible chance of beating advanced melanoma.”
The discovery of the subtypes, which are defined by the presence or absence of signature mutations on the genes, will not only help doctors develop more personalised care, they could also help researchers create predictive models to guide patient care.
The TCGA project overall was funded by the US National Institutes of Health and National Human Genome Research Institute, with MIA’s contribution supported by funding from the National Health and Medical Research Council. MIA clinicians, patients and donors continue to work together to establish and grow MIA’s tumour bank and database, which made this milestone in melanoma research possible.
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.